Recently, market rumors suggested that GuanHao Bio was in talks with BrainCo regarding a potential collaboration, drawing investor attention. In response, GuanHao Bio officially clarified that, as of now, the company has not engaged in any form of cooperation with BrainCo, nor does it have any related plans. GuanHao Bio emphasized that while it closely monitors advancements in cutting-edge fields such as brain science, neuromodulation, and regenerative medicine—and actively evaluates strategic partnership opportunities—all official information will be disclosed through formal channels.GuanHao Bio is a leading Chinese enterprise in biomaterials and regenerative medicine, with a long-standing focus on innovative product development in areas including neural repair, ophthalmology, and plastic surgery. BrainCo, on the other hand, is a high-tech company specializing in non-invasive brain-computer interface (BCI) technologies, with applications in education, rehabilitation, and wellness. Although their technological focuses show potential complementarity, there has been no substantive contact between the two parties to date.The company urges investors to remain cautious and avoid acting on unverified market rumors. Should any significant collaboration occur in the future, GuanHao Bio will promptly disclose the information in accordance with regulatory disclosure requirements.
近日，有市场传闻称冠昊生物与强脑科技（BrainCo）正在洽谈合作事宜，引发投资者关注。对此，冠昌生物于官方渠道明确回应：截至目前，公司暂未与强脑科技展开任何形式的合作，亦无相关合作计划。冠昊生物强调，公司始终密切关注脑科学、神经调控及再生医学等前沿领域的技术发展，并积极评估潜在的战略合作机会，但一切以官方公告为准。冠昊生物作为国内领先的生物材料和再生医学企业，长期致力于神经修复、眼科、整形外科等领域的创新产品研发。而强脑科技则是一家专注于非侵入式脑机接口技术研发的高科技公司，在教育、康复、健康等领域拥有应用场景。尽管双方在技术方向上存在一定互补性，但目前尚无实质性接触。公司提醒广大投资者注意风险，勿轻信未经证实的市场传言。未来如有重大合作进展，冠昊生物将严格按照信息披露相关规定及时公告。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/15901.html